Clinical Trial Search

Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Number of Subjects With Daily Headache Who Have Continuous Headache — 18; 27 participants

Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001

Primary: Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12 — 232; 35…

Primary: Change From Baseline in Monthly Migraine Days — -4.18; -6.64; -6.63 migraine days / month — p=<0.001

Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants

Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks

Primary: Headache Days — 23.64; 24.33 Days — p=0.83

Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants

Primary: The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary — 51.0; 30.8 Percentage of…

Primary: Frequency of Moderate to Severe Headache Days — 9.3; 9.1 days

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Change From Baseline in Monthly Migraine Days at the Last Month (Month 3) of the Double-blind Treatment Period (DBTP) — -4.20; -4.79; -3.10 Migraine days/month — p=0.002

Primary: DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -0.6; -3.7; -4.1 days/month…

Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -2.28; -2.18; -2.39; -3.40 migraine days / month — p=0.021

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days

Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -1.84; -2.88 migraine days / month — p=< 0.001

Primary: Total Number of Responders — 17 Participants

Primary: Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7. — -7.61; -6.67; -9.72; -5.22 days

Primary: Mean Change in the Number of Monthly Migraine Headache Days — -8.17; -7.78; -5.77 number of days

Primary: Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study Drug — -2.5…

Primary: Number of Participants With Adverse Events — 398; 302; 34; 0 Participants

Primary: Percent Change of Migraine Headache Days Compared to Baseline — -8.06; -56.37 percent migraine headache days per month

Primary: Change in Migraine Characteristics — 43; 2; 17 Participants